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Abstract
The blood coagulation cascade is essential for hemostasis but excessive activation can cause
thrombosis. Importantly, recent studies have identified factors that contribute to thrombosis but
not hemostasis. These include factor XII (FXII), tissue factor-positive microparticles (MPs) and
neutrophil extracellular traps (NETs). Recent studies have shown that FXII plays a role in
thrombosis but not hemostasis. FXII is activated in vivo by a variety of negatively-charged
polyphosphates, which include extracellular RNA, DNA and inorganic polyphosphate (PolyP) that
are released during cell damage and infection. These findings have triggered the development of
nucleic acid-binding polymers as a new class of anticoagulant drug. Other studies have analyzed
the role of MPs in experimental thrombosis. MPs are small membrane vesicles released from
activated or apoptotic cells. We and others have found that tissue factor-positive MPs enhance
thrombosis in mouse models and are elevated in the plasma of pancreatic cancer patients. Finally,
NETs have been shown to contribute to experimental venous thrombosis in mouse models and are
present in human thrombi. NETs are composed of chromatin fibers that are released from
neutrophils undergoing cell death. NETs can capture platelets and increase fibrin deposition. The
recent advances in our understanding of the factors contributing to thrombosis in animal models
provide new opportunities for the development of safer anticoagulant drugs.
This review will discuss recent advances in our understanding of the role of inorganic
polyphosphates (PolyP) in hemostasis and thrombosis, and factors that contribute to
thrombosis but not hemostasis. We will summarize recent studies on three new players:
FXII, tissue factor (TF)-positive microparticles (MPs) and neutrophil extracellular traps
(NETs).
The coagulation protease cascade
The coagulation cascade is essential for hemostasis and has been studied for many years.
However, we still have a limited number of drugs that are used clinically to prevent and treat
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thrombosis. Importantly, all of these drugs are associated with bleeding side effects because
they target key proteases in the coagulation cascade. This includes the new oral
anticoagulant drugs (NOACs), which target either factor Xa or thrombin.
The coagulation cascade can be divided into the extrinsic, intrinsic and common pathways.
The extrinsic pathway produces small amounts of thrombin that activates a variety of
components in the cascade that allows amplification of the cascade via the intrinsic pathway
to produce large amounts of thrombin (Figure). Thrombin cleaves fibrinogen to fibrin
resulting clot formation (Figure). The extrinsic pathway of the coagulation cascade is
initiated upon the exposure of extravascular TF to blood. Formation of the TF/FVIIa
complex triggers the coagulation cascade by activating both FX and FXI (1). This pathway
is “extrinsic” to blood since significant levels of TF are not present in blood in healthy
individuals. The extrinsic pathway is essential for hemostasis. The intrinsic pathway of the
coagulation cascade is comprised of three proteases, FXIIa, FXIa, FIXa and the cofactor
FVIIIa. Under physiologic conditions, this pathway is activated by thrombin cleavage of
FXI (2). Deficiencies in FIX and VIII lead to mild to severe bleeding in humans (hemophilia
B and A, respectively) while FXI deficiency results in only a minor increase in bleeding
with injury (hemophilia C) (3). The intrinsic pathway can be activated ex vivo by
negatively-charged compounds, such as kaolin, that activates FXII. FXII activation has been
showed to directly modify fibrin clot structure by increasing fibrin fiber density (4). The
common pathway consists of the proteases FXa, thrombin and the cofactor FVa. Proteases in
the common pathway are the major targets of current anticoagulant therapy (Figure).
Renne and colleagues were the first to show that FXII deficient mice exhibit reduced
thrombosis in several different arterial thrombosis models without any increase in tail vein
bleeding time (5). This observation was important because it suggested that thrombosis
could be separated from hemostasis and suggested that FX could be a new target for the
development of safe anticoagulant drugs. FXI deficient mice have no apparent hemostatic
defects and humans with FXI deficiency have a small increase in bleeding after injury (refs).
These observations suggest that inhibition of FXIa might also reduce thrombosis with
minimal effects on hemostasis.
Despite the knowledge that FXII is activated by negatively-charged substances it was
unclear what was activating FXII in vivo. Several candidates have been proposed as FXII
activators over the years. Preissner and colleagues reported that extracellular RNA bound to
both FXII and FXI and suggested that this was the “long sought after natural foreign
surface” for the activation of the intrinsic pathway (6). There is also evidence that DNA-rich
NETS and PolyP activate FXII and initiate the intrinsic pathway of the coagulation cascade
(7, 8).
There is a large literature on the effect of different FXII and FXI inhibitors on thrombosis in
various animal models (Figure). FXII inhibitors have been shown to reduce both venous and
arterial thrombosis in multiple animal models without an associated increase in bleeding
(9-11). These inhibitors include H-D-Pro-Phe-Arg-chloromethylketine and infestin 4, which
was cloned from the midgut of the blood-sucking insect Triatoma infestans. Inhibitory anti-
FXI antibodies and small molecules have been shown to reduce both venous and arterial
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thrombosis in mice, rats, rabbits, and baboons without an associated increase in bleeding
(12-16). Antisense oligonucleotides (ASOs) have also been used to reduce levels of different
coagulation factors and determine the effect on thrombosis. ASOs target complementary
mRNA resulting in RNA degradation and a reduction in protein expression. They are
particularly promising for the targeting of genes expressing coagulation proteins because of
the high level of sensitivity of liver tissue to ASOs (17). FXII and FXI ASOs have been
shown to reduce arterial and venous thrombosis in various animal models without increasing
bleeding (9, 11, 17, 18).
Role of PolyP in hemostasis and thrombosis
PolyP is a highly anionic linear polymer that is synthesized from ATP (19). In humans, this
molecule is secreted by platelets after activation (19). Morrissey and colleagues were the
first to report a role for PolyP in blood coagulation (20). PolyP was shown to affect
numerous steps in the coagulation cascade, including activating FXII, enhancing the
activation of FV, increasing the activity of thrombin-activated fibrinolysis inhibitor (TAFI),
and inhibiting tissue factor pathway inhibitor (TFPI) (20). Other studies have extended this
early observation and have also demonstrated that PolyP enhances fibrin clot structure
stability (7, 21, 22). These results led to the suggestion that PolyP may be considered for use
as a general procoagulant agent in the treatment of patients with hemostatic defects (23).
Microorganisms store PolyP in subcellular organelles termed acidocalcisomes. In
mammalian platelets PolyP is stored in dense granules. There are important differences
between bacterial and platelet PolyP. Bacteria produce long-chain PolyP (up to several
thousand phosphate units) whereas platelets contain short-chain PolyP (60-100 phosphates
units)(19). PolyP of different size have different activities in the coagulation cascade (22).
Long chain PolyP polymers (>250-500mers) have been shown to be a strong activator of
FXII and affect fibrin clot structure (22). On the other hand, shorter polymers (<100mers)
increase FV activation and inhibit TFPI (22). Polyphosphate in both size categories also
serve as a cofactor for thrombin activation of FXI (24). Renne and colleagues showed that
human platelet PolyP induced pulmonary embolism and increased vascular permeability in
mice in a FXII-dependent manner (7). The study concluded that “PolyP links platelet plug
formation (primary hemostasis) and fibrin generation (secondary hemostasis). If platelet
PolyP is playing a central role in blood coagulation by activating FXII then one would
expect FXII deficient humans and mice to have a major hemostatic defect. However, FXII
deficient humans and mice demonstrate normal hemostasis (3). Importantly, a second group
could not reproduce the in vivo results produced by Renne and colleagues using the mouse
pulmonary embolism model and concluded that platelet PolyP is a weak activator of FXII
(25). Drs. Renne and Morrissey provided separate rebuttals to the Faxalv study and
demonstrated that the negative in vivo results may be due to the extended storage of PolyP
resulting in degradation and loss of activity (26, 27). The role of platelet PolyP as a weak
activator as opposed to a strong activator of FXII is supported by previous studies (22).
Clearly, more studies are needed to resolve this controversy and determine the role of
platelet PolyP in regulating the coagulation cascade.
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Does platelet PolyP play a role in hemostasis? This question was addressed in a recent study
that generated mice deficient in inositol hexakisphosphate 6 (IP6) kinase, which is an
enzyme required for the synthesis of platelet PolyP (28). Platelets from these mice had a 3-
fold reduction in phosphate levels. These IP6 kinase knockout mice had slower platelet
aggregation, increased plasma clotting times, and altered fibrin structure. Furthermore, the
mice had prolonged tail vein bleeding times and were resistant to thromboembolism (28).
Since the mice had defects in both platelet aggregation and clotting it is unclear if the in vivo
hemostatic defect were due to a primary effect on platelets and/or coagulation. Nevertheless,
this genetic approach supports the notion that PolyP is a general procoagulant agent.
The above polyphosphate studies have triggered the development of new anticoagulant
drugs that can inactivate these polyphosphates. Sullenger and colleagues screened a variety
of nucleic acid binding polymers and identified a cationic poly (amido amine) (PAMAM)
dendrimer called PAMAM-G3 that prevented thrombosis without increasing tail vein
bleeding in mice (29). Similarly, Morrissey and colleagues found that the cationic
compounds 1.0 dendrimer and polymyxin B reduce both venous and arterial thrombosis in
mice (30).
Microparticles in hemostasis and thrombosis
MPs are small (0.1-1.0 μm) membrane vesicles released from activated or apoptotic cells
and cells that have undergone oncogenesis (31-33). These vesicles were originally described
as “platelet dust” that was observed being released from activated platelets by microscopy
(34). MPs are formed by the outward blebbing of the plasma membrane with subsequent
release after proteolytic cleavage of the cytoskeleton (32, 35). The majority of MPs have
phosphatidylserine (PS) exposed on their surface, although PS-negative MPs can be formed
after platelet activation (36). They contain a selective group of cell surface proteins, which
includes TF (32, 37). MPs are procoagulant due to the presence of negatively-charged
phospholipids, such as PS, and TF on the surface (38-40). TF binds FVII/FVIIa and PS
facilitates the assembly of positively-charged coagulation factor complexes (41-43). There is
indirect evidence for a role of MPs in hemostasis (44). Injection of soluble P-selectin-Ig into
hemophilia A mice resulted in an increase in the number of circulating MPs, including TF-
positive MPs, and a correction of the tail-vein bleeding time (44). Similarly, infusion of red
blood cell-derived MPs into thrombocytopenic rabbits corrected ear bleeding time in a dose-
dependent manner (45). However, there is no evidence that circulating MPs contribute to
hemostasis in healthy individuals. The majority of MPs in blood in healthy individuals are
derived from platelets and it is difficult to separate the role of platelet-derived MPs in
hemostasis from the role of the platelets themselves (46).
MP enhancement of experimental thrombosis is well documented. For instance, injection of
MPs isolated from cardiac bypass surgery patient plasma was shown to enhance thrombosis
in a TF dependent manner using a rat IVC stenosis model of venous thrombosis (47). One
study examined the docking of tumor-derived MPs to sites of ferric chloride-induced
mesenteric vessel injury and laser-induced cremaster arteriole injury in vivo (48). MPs
derived from PANC02 mouse pancreatic adenocarcinoma tumors accumulated at sites of
vascular injury and thrombosis (48). This MP accumulation was reduced by treatment of the
Geddings and Mackman Page 4






















mice with an inhibitory P-selectin antibody (48). Mouse pancreatic tumor-derived MPs were
also found to enhance ferric chloride-induced thrombosis in mice (48). However, cleavage
of surface ligands on these tumor MPs by trypsinization or treatment of mice with an
inhibitory P-selectin antibody prior to MP infusion attenuated the MP-induced enhancement
of thrombosis (48). We found that growth of human pancreatic tumors expressing TF was
associated with release of TF-positive MPs into the circulation and activation of coagulation.
In addition, injection of TF-positive tumor-derived MPs enhances thrombosis in an inferior
vena cava (IVC) stenosis model of venous thrombosis (49).
Statin treatment is associated with a reduction in venous thrombosis (50, 51). The Jupiter
trial demonstrated a reduction in VTE in patients with high levels of C-reactive protein but
normal blood lipids that were prophylactically treated with rosuvastatin (50). Our laboratory
has shown that hypercholesterolemia can induce monocyte TF expression and release of TF-
positive MPs in vivo (52). Moreover, we found that simvastatin treatment attenuated this
increase in TF-positive MPs in both hypercholesterolemic mice and in monkeys (52).
Patients with a variety of thrombotic disease often have elevated levels of TF-positive MPs
suggesting that they may contribute to the prothrombotic state and thrombosis (33, 35, 53).
We hypothesize that TF-positive MPs could represent a new target for anticoagulant therapy
that would have minimal effect on hemostasis. A concern of this therapy, however, would be
that it would only be effective in prothrombotic disease states that are shown to be
dependent on MPs. While there is evidence for a role of MPs in thrombosis in vivo in some
diseases such as pancreatic cancer associated thrombosis, definitive evidence for a reduction
in thrombosis associated with targeting MPs in patients does not yet exist. Potential
strategies would include blocking the formation, increasing the clearance and/or preventing
the docking of the MPs to the activated endothelium. P-selectin inhibitors are already in
development for use as anti-thrombotic agents (54-56). However, these inhibitors block
platelet aggregation which would affect hemostasis, potentially resulting in bleeding side
effects.
NETs and thrombosis
NETs are primarily released by activated neutrophils via a cell death program called
NETosis that is distinct from either apoptosis or necrosis (57). NETS consist of nucleic acids
decorated with histones and other proteins that are involved in the entrapment and killing of
both Gram-negative and Gram-positive bacteria as well as fungi in innate immunity (58, 59).
NETosis involves chromatin decondensation followed by the fragmentation of the nuclear
envelope and neutrophil granules allowing for the mixing of components within the cell
before plasma membrane lysis and NET release (57). Non-suicidal pathways of NETosis
have also been identified which involve the release of nuclear or mitochondrial DNA by
living cells through the budding of NET-filled vesicles (60-62). Of note, simply assaying for
free DNA or histones in the plasma is not sufficient evidence for NET release as free DNA
can also be released in other forms of lytic cell death (59).
NETs have been shown to enhance experimental venous and arterial thrombosis through
multiple mechanisms. As mentioned above, they provide a negatively-charged surface for
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the activation of FXII (63). Histones, a major component of NETs, have also been shown to
induce activation and aggregation of platelets (64, 65). Neutrophils that have been
stimulated to release NETs activate FXII in vitro in a histone H2A and H2B dependent
manner (63). NETs enhance activation of the extrinsic pathway of the coagulation cascade
through the inactivation of TFPI (66). They also increase venous thrombosis by binding both
platelets and red blood cells (64). These structures have been imaged within venous thrombi
in both mice and primates (63, 64, 67, 68). Importantly, mice with impaired NET formation
have a decreased incidence of thrombosis in the IVC stenosis model (67). Two studies have
demonstrated protection from venous thrombosis in mice that have been treated with DNase
1, which degrades cell free DNA and NETs (63, 68). The anticoagulant heparin has been
shown to displace histones from NETs resulting in their degradation and a reduction in
venous thrombosis (63, 64). Similarly, carotid artery thrombosis is reduced in mice that are
deficient in two neutrophil serine proteases that are present on NETs (66). Infusion of
purified histones into mice has also been shown to enhance venous thrombosis (68).
Polysialic acids have been shown to neutralize histones resulting in a reduction in NET-
mediated cytotoxicity, although these agents have not yet been tested in a thrombosis model
(69).
At present, there is little evidence that NETs are required for hemostasis. The tail vein
bleeding time was prolonged two-fold in mice that were deficient in two neutrophil serine
proteases that are known to be present on NETs (66). Also, while histones are only one
component of NETs, it is of note that infusion of histones into mice causes
thrombocytopenia that is associated with a profound increase in tail vein bleeding time (65).
Recent studies provide evidence for an association between NET release and thrombosis in
humans (70-73). Patients diagnosed with acute VTE have been shown to have increased
plasma nucleosomes and activated neutrophils (72). Further, both acute VTE and thrombotic
microangiopathies are associated with increased plasma DNA and myeloperoxsidase after
diagnosis (70, 71). Finally, neutrophils and NETs were present in thrombi isolated from
patients with acute myocardial infarction (73).
Conclusion
There are many people that have contributed to our increased understanding of the pathways
involved in hemostasis and thrombosis. The discovery that PolyP affects many aspects of
the clotting cascades suggests that it may be a useful hemostatic agent for the treatment of a
variety of bleeding disorders. In contrast, several factors have been identified that appear to
contribute to pathologic thrombosis but not hemostasis. These include FXII, TF-positive
MPs and NETs. Inhibition of FXII activators with nucleic acid polymers may provide a safe
way to reduce thrombosis. However, these drugs may only be effective inpatients in which
thrombosis is triggered via the intrinsic pathway and are likely to be less efficacious than
current anticoagulant drugs that target the common pathway of coagulation. At present, it is
unclearif interfering with NET formation will be a viable approach to reducing arterial and
venous thrombosis in patients.
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Separating thrombosis and hemostasis in the coagulation cascade.
Current anticoagulant therapies target the common pathways and, as a result, have
significant bleeding side effects. Targeting thrombotic triggers as opposed to targeting the
pathways involved in hemostasis could potentially allow for the creation of novel
antithrombotic agents with minimal bleeding side effects.
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